CT scan to check coronary bypass graft openness after CABG in ACS patients on aspirin alone versus aspirin plus ticagrelor
Coronary CT Angio Evaluating Graft Patency in ACS Patients Treated With DAPT or Single ASA After CABG (CoCAP)
This project will use CT scans to see if people who had coronary bypass surgery for acute coronary syndrome have better graft openness when taking aspirin plus ticagrelor (DAPT) compared with aspirin alone.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 360 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Linkoeping Academic / other |
| Locations | 6 sites (Bergen and 5 other locations) |
| Trial ID | NCT04783701 on ClinicalTrials.gov |
What this trial studies
This is an observational follow-up of patients previously enrolled in the TACSI trial who underwent CABG for acute coronary syndrome. Participants will be followed 12–36 months after surgery and undergo coronary computed tomography angiography (CCTA) to determine graft patency. The main comparison is between patients managed with single aspirin versus dual antiplatelet therapy including ticagrelor. Standard exclusions include irregular heart rhythm (e.g., atrial fibrillation), significant renal impairment, high body weight, or prior severe contrast allergy.
Who should consider this trial
Good fit: Ideal candidates are people who had CABG for acute coronary syndrome and were previously enrolled in the TACSI trial, who can undergo CCTA and meet the study's medical criteria.
Not a fit: Patients with atrial fibrillation, severe kidney dysfunction (eGFR <45), body weight over 120 kg, severe iodine contrast allergy, inability to communicate, or who were not in TACSI are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the findings could help doctors choose antiplatelet regimens that better preserve bypass graft openness and potentially reduce repeat interventions after CABG.
How similar studies have performed: Previous trials and observational studies have shown mixed results, with some evidence that DAPT can improve vein graft patency but overall evidence remains inconclusive.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Previously included in TACSI-trial Exclusion Criteria: * Highly irregular heart rhythm (i.e. atrial fibrillation) * Chronic kidney disease with estimated glomerular filtration rate (eGFR) \<45ml/min/1,73m2 * Body weight \>120 kg * Previous severe allergic reaction (i.e. anaphylactic reaction) to iodine-based contrast agents * Not able to communicate * Not willing to participate
Where this trial is running
Bergen and 5 other locations
- Department of Heart Disease, Haukeland University Hospital — Bergen, Norway (Enrolling_by_invitation)
- St Olavs University Hospital — Trondheim, Norway (Not_yet_recruiting)
- Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine — Gothenburg, Sweden (Enrolling_by_invitation)
- Dep of Vascular and Thoracic Surgery — Örebro, Sweden (Active_not_recruiting)
- Department of Cardiothoracic Surgery Karolinska University Hospital — Stockholm, Sweden (Enrolling_by_invitation)
- University Hospital Linköping — Linköping, Östergötland County, Sweden (Recruiting)
Study contacts
- Study coordinator: Jonas Holm, MD, PhD
- Email: jonas.holm@regionostergotland.se
- Phone: +46101034498
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.